Literature DB >> 22552358

Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.

Masashi Takano, Tomoko Goto, Masafumi Kato, Naoki Sasaki, Morikazu Miyamoto, Kenichi Furuya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22552358     DOI： 10.1007/s10147-012-0404-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  13 in total

1.  Recurrent ovarian clear cell carcinoma: complete remission after radiation in combination with hyperthermia; a case study and in vitro study.

Authors:  M Suzuki; Y Saga; S Tsukagoshi; N Tamura; I Sato
Journal:  Cancer Biother Radiopharm       Date:  2000-12       Impact factor: 3.099

2.  Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.

Authors:  Kiyoshi Yoshino; Takayuki Enomoto; Masami Fujita; Yutaka Ueda; Toshihiro Kimura; Eiji Kobayashi; Tateki Tsutsui; Tadashi Kimura
Journal:  Int J Clin Oncol       Date:  2011-12-10       Impact factor: 3.402

3.  Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer.

Authors:  S Wilailak; V Linasmita; S Srisupundit
Journal:  Anticancer Drugs       Date:  2001-10       Impact factor: 2.248

Review 4.  Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.

Authors:  N Takai; H Utsunomiya; Y Kawano; K Nasu; H Narahara; I Miyakawa
Journal:  Arch Gynecol Obstet       Date:  2002-12       Impact factor: 2.344

5.  Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.

Authors:  J Al-Barrak; J L Santos; A Tinker; P Hoskins; C B Gilks; H Lau; K D Swenerton
Journal:  Gynecol Oncol       Date:  2011-04-03       Impact factor: 5.482

6.  Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.

Authors:  H Utsunomiya; J Akahira; S Tanno; T Moriya; M Toyoshima; H Niikura; K Ito; Y Morimura; Y Watanabe; N Yaegashi
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

7.  Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.

Authors:  David R Crotzer; Charlotte C Sun; Robert L Coleman; Judith K Wolf; Charles F Levenback; David M Gershenson
Journal:  Gynecol Oncol       Date:  2007-02-09       Impact factor: 5.482

8.  Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.

Authors:  Masashi Takano; Yoshihiro Kikuchi; Kazuya Kudoh; Tomoko Goto; Kenichi Furuya; Ryoko Kikuchi; Tsunekazu Kita; Keiichi Fujiwara; Tanri Shiozawa; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2011-01-18       Impact factor: 3.402

9.  Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.

Authors:  T Sugiyama; M Yakushiji; T Nishida; K Ushijima; N Okura; J Kigawa; N Terakawa
Journal:  Cancer Lett       Date:  1998-06-19       Impact factor: 8.679

10.  A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.

Authors:  Gabriella Ferrandina; Francesco Legge; Valentina Mey; Sara Nannizzi; Simona Ricciardi; Marco Petrillo; Giacomo Corrado; Giovanni Scambia
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-11       Impact factor: 3.333
View more
  5 in total

1.  Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma.

Authors:  Hiroki Ishibashi; Masashi Takano; Morikazu Miyamoto; Hiroaki Soyama; Hiroko Matsuura; Tadashi Aoyama; Tomoyuki Yoshikawa; Kento Kato; Hitoshi Tsuda; Kenichi Furuya
Journal:  Mol Clin Oncol       Date:  2017-10-23

2.  X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.

Authors:  M Miyamoto; M Takano; K Iwaya; N Shinomiya; M Kato; T Aoyama; N Sasaki; T Goto; A Suzuki; J Hitrata; K Furuya
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

3.  Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.

Authors:  Shiro Suzuki; Kiyosumi Shibata; Fumitaka Kikkawa; Tetsuya Nakatsura
Journal:  Hum Vaccin Immunother       Date:  2013-11-21       Impact factor: 3.452

Review 4.  The role of immune checkpoint inhibition in the treatment of ovarian cancer.

Authors:  Stéphanie L Gaillard; Angeles A Secord; Bradley Monk
Journal:  Gynecol Oncol Res Pract       Date:  2016-11-24

5.  Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.

Authors:  Shiro Suzuki; Jun Sakata; Fumi Utsumi; Ryuichiro Sekiya; Hiroaki Kajiyama; Kiyosumi Shibata; Fumitaka Kikkawa; Tetsuya Nakatsura
Journal:  Oncoimmunology       Date:  2016-09-30       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.